DR. JULES BERNARD PUSCHETT, M. D.
Osteopathic Medicine in Temple, TX

2011004, Feb 24, 2011

Feb 16, 2010

12/706021

Jules B. Puschett - Temple TX, US

A61K 38/43, G01N 33/00, G01N 33/52

424 941, 436 86, 422430

A method of testing a patient for hypertension includes providing a urine specimen from the patient, performing a first test on the urine specimen to determine if volume expansion hypertension exists by measuring the level of marinobufagenin in the urine specimen, performing a second test on the urine specimen to determine if vasoconstrictive hypertension exists by measuring the level of angiotensinogen in the urine specimen, and performing the first and second tests on the urine specimen substantially simultaneously without either test having an adverse effect on the other test. The tests may employ a test strip having a first region for use in the first test and a second region for use in the second test with each region effecting a visible change if the condition for which the test is being formed is found to exist. A related method of treatment and a related test kit are also disclosed.

2011000, Jan 13, 2011

May 17, 2010

12/781464

JULES B. PUSCHETT - Temple TX, US

SCOTT AND WHITE MEMORIAL HOSPITAL AND SCOTT, SHERWOOD, AND BRINDLEY FOUNDATION - TEMPLE TX

G01N 33/50

436 93, 422 681

A method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal persons, and if the marinobufagenin concentration is substantially above the concentration of a normal person, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal person. The body specimen may be blood or urine. If a substantial elevation is deemed to exist, the magnitude from the departure from the concentration of a normal person may be employed in determining the timing and nature of treatment provided to the patient. The method may be repeated at predetermined intervals to monitor changes in the marinobufagenin with time. Corresponding apparatus is provided.

8642568, Feb 4, 2014

Jun 15, 2011

13/160735

Jules B. Puschett - Temple TX, US
Lee Shapiro - Jarrell TX, US

A01N 45/00, A61K 31/56, A61K 31/58

514 26, 514170, 514172

Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal patients, and if the marinobufagenin concentration is substantially above the concentration of a normal patient, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal patient. The body specimen may be blood, urine, or cerebrospinal fluid. If a substantial elevation is deemed to exist, the magnitude of the departure from the concentration of a normal patient may be employed in determining the timing and nature of treatment provided to the patient.

8080539, Dec 20, 2011

Jun 23, 2010

12/821880

Jules B. Puschett - Temple TX, US

Scott and White Healthcare - Temple TX

A61K 31/56, A61K 31/58, A01N 45/00

514170, 514172, 514 26, 514 25, 536 41

A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia.

2011020, Aug 25, 2011

Dec 21, 2010

12/974482

JULES B. PUSCHETT - Temple TX, US
Daniel Romo - College Station TX, US
Luc R. Berghman - College Station TX, US
Daad Ali Abi-Ghanem - College Station TX, US
Xinzhong Lai - Edison NJ, US

SCOTT & WHITE HEALTHCARE - Temple TX

G01N 33/566, C07K 14/00, C07K 14/765, C07J 19/00, C07J 43/00, C07K 14/435

435 792, 530410, 530363, 540 4, 540 83, 530409, 530386, 436501

The present invention is directed toward a method for determination of marinobufagenin concentration in a body specimen through conjugation of marinobufagenin to a suitable protein, thereby creating a conjugate which will trigger an antibody response in a host. The conjugated marinobufagenin is immunogenic. The antibodies so produced may be employed in an ELISA test to ascertain the concentration of marinobufagenin in a body specimen. A number of unique compounds are created in the process and are disclosed. An ELISA assay may be employed.

8048868, Nov 1, 2011

Jul 13, 2009

12/501541

Jules B. Puschett - Temple TX, US

Scott & White Healthcare - Temple TX

A61K 31/56, A61K 31/58, A01N 45/00

514170, 514172, 514 26, 514 25, 536 41

A method of preventing preeclampsia including administering to a patient during an early stage of pregnancy a prophylactically-effective amount of resibufogenin. The administration of resibufogenin is periodically repeated. The method serves to prevent hypertension, proteinuria, and intrauterine growth restriction.